Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
IDE397 (MAT2A inhibitor) - Molecular Sherlock
BYUNGJUNE PARK on LinkedIn: IDEAYA Biosciences' IDE397 has shown ...
IDE397 (GSK-4362676; MAT2A-IN-9) | CAS 2439277-80-0 | AbMole BioScience ...
IDE397 (GSK-4362676) | MAT2A Inhibitor | CAS 2439277-80-0 | Selleck ...
IDEAYA Announces Phase 1/2 Expansion for IDE397 and Trodelvy ...
IDEAYA Biosciences Advances Synthetic Lethality With IDE397 Success ...
Paolo Tarantino: Intersecting data with the MAT2A inhibitor IDE397 in ...
IDE397 + Trodelvy Combo in MTAP-Deletion Cancers: A Precision Oncology ...
(PDF) 492TiP A phase I study of synthetic lethal, IDE397 (MAT2A ...
Ideaya Biosciences reports Phase 2 data for MAT2A inhibitor IDE397 ...
IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a ...
IDEAYA choses monotherapy expansion dose for IDE397 trial
IDE397 | 2439277-80-0 | AbMole | GSK-4362676; MAT2A-IN-9
D-Day For IDEAYA - IDE397 Data To Be Unveiled Tomorrow
IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular ...
IDEAYA Biosciences (NASDAQ:IDYA) shows strong phase 2 IDE397 results
Ide397 – Application in Therapy and Current Clinical Research
Part 1: Dose Exploration of AMG 193 Combined With IDE397 for Non-Small ...
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion ...
IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data ...
IDE397 Shows Preliminary Efficacy in MTAP+ NSCLC and Urothelial Cancer
IDE397 shows promise in MTAP-deletion urothelial carcinoma
AMG 193 + IDE397 for Solid Cancers Clinical Trial 2025 | Power
IDE397 Combo Displays Promising Activity in MTAP-Deletion Urothelial ...
首创MAT2A抑制剂IDE397治疗MTAP缺失的晚期尿路上皮癌和非小细胞肺癌，疾病控制率93%！ - 知乎
Slide 13
IDEAYA与安进达成临床试验合作，评估MAT2A-PRMT5 合成致死组合
IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating ...
LOGO
研究性MAT2A抑制剂IDE397早期临床结果积极，超90%晚期癌症患者疾病得到控制-上市-医保-临床适应症-香港济民药业
IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First ...
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data ...
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination ...
Positive Interim Phase II Data Show Strong Overall Response and Disease ...
Abstract B027: The MAT2A inhibitor IDE397: a novel combination backbone ...
IDE397: a novel MAT2A inhibitor in patients with solid tumors harboring ...
Abstract 1278: MAT2A inhibitor, IDE397, displays broad anti-tumor ...
Slide 16
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 ...
IDEAYA Announces Presentations at AACR Annual Meeting 2023 for ...
IDE-397(IDE-397) - 药物靶点：Mat2A_在研适应症：非小细胞肺癌，甲硫腺苷磷酸化酶缺失实体瘤，尿路上皮癌_专利_临床_研发
MAT2A antagonist | MAT2A inhibitor |MAT2A agonist |MAT2A activator
IDE-397(IDE-397) - 药物靶点：Mat2A_在研适应症：食管癌，非小细胞肺癌，甲硫腺苷磷酸化酶缺失实体瘤_专利_临床_研发
MAT2A Inhibitor Screening Assay Kit MAT2A 71402
Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality ...
Slide 12
Synthetic Lethality. $RPTX $IDYA : Biotechplays
IDEAYA announces further Gilead sciences clinical study collaboration ...
Slide 17
Slide 11
Slide 14
MAT2A | Insilico Medicine
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by ...
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for ...
MAT2A-IN-9 | Methionine Adenosyltransferase (MAT) | TargetMol
IDEAYA reports positive data from Phase II cancer therapy trial
IDEAYA initiates subject dosing in Phase I bladder cancer trial
아이디야, '합성치사' MAT2A+트로델비 방광암 "히트" - 바이오스펙테이터
Pharmacologic targeting of MAT2A with in vivo tool molecule selectively ...
Drug combination screens uncover synergistic interactions between ...
MAT2A inhibitors to treat BK polyomavirus disease – Cambridge Enterprise
Slide 3
MAT2A-IN-14 | MAT2A Inhibitoer | MedChemExpress
Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer ...
MAT2A inhibitor 1 | MATA2 Inhibitor | MedChemExpress
甲硫氨酸腺苷转移酶2A (MAT2A)作为抗癌靶点的结构、功能和抑制剂 - 知乎
合成致死领域药物研发现状医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Slide 5
Pipeline – IDEAYA Biosciences
(PDF) Fragment-Based Design of a Potent MAT2a Inhibitor and in Vivo ...
Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric ...
IDE397联合Trodelvy：MTAP缺失尿路上皮癌治疗新希望，临床研究揭示积极疗效 - MedFind
Ideaya Biosciences: Lots Of 'Shots On Goal' And Upcoming Potential ...
Ideaya Begins Testing MAT2A Inhibitor, Trodelvy in Phase I MTAP-Deleted ...
Slide 9
MTAP缺失尿路上皮癌靶向治疗消息：IDE397初显抗肿瘤活性|医疗|皮癌|尿路|患者|缺失_新浪新闻
